PAVmed (PAVM) 10-Q 28 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 26, 2020
Document And Entity Information
Entity Registrant Name	PAVmed Inc.
Entity Central Index Key	0001624326
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		46,926,897
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash	$ 8,731	$ 6,219
Prepaid expenses and other current assets	692	328
Total current assets	9,423	6,547
Other assets	691	693
Total assets	10,114	7,240
Current liabilities
Accounts payable	4,157	2,353
Accrued expenses and other current liabilities	1,523	1,386
Senior secured convertible notes at fair value	20,663	8,139
Total liabilities	26,343	11,878
COMMITMENTS AND CONTINGENCIES (NOTE 7)
Stockholders' Equity (Deficit)
Common stock, par value $0.001; 100,000 shares authorized; 44,134 and 40,479 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	44	41
Additional paid-in capital	50,896	47,554
Accumulated deficit	(68,259)	(53,715)
Total PAVmed Inc. Stockholders' Deficit	(14,996)	(3,824)
Noncontrolling interest	(1,232)	(814)
Total Stockholders' Deficit	(16,229)	(4,638)
Total Liabilities and Equity (Deficit)	10,114	7,240
Series B Convertible Preferred Stock [Member]
Stockholders' Equity (Deficit)
Preferred stock, par value $0.001, 20,000 shares authorized;	$ 2,322	$ 2,296

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value per share		$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	44,133,745	40,478,861
Common stock, shares outstanding	44,133,745	40,478,861
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	1,156,000	1,158,000
Preferred stock, shares outstanding	1,156,000	1,158,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenue
General and administrative expense	2,625	1,693
Research and development expense	2,628	1,451
Total operating expenses	5,253	3,144
Loss from operations	(5,253)	(3,144)
Other income (expense)
Interest expense	(52)
Change in fair value - Senior Secured Convertible Notes	(8,008)	(559)
Offering costs - issue of Senior Secured Convertible Note - Series B	(410)
Debt extinguishments loss - Senior Secured Convertible Notes	(1,188)	(1)
Other income (expense), net	(9,658)	(560)
Loss before provision for income tax	(14,911)	(3,704)
Provision for income taxes
Net loss - before noncontrolling interest	(14,911)	(3,704)
Net loss attributable to noncontrolling interest	436	169
Net loss - attributable to PAVmed Inc.	(14,475)	(3,535)
Less: Series B Convertible Preferred Stock dividends earned	(70)	(65)
Net loss attributable to PAVmed Inc. common stockholders	$ (14,545)	$ (3,600)
Net loss per share - attributable to PAVmed Inc. - basic and diluted	$ (0.33)	$ (0.13)
Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted	$ (0.33)	$ (0.13)
Weighted average common shares outstanding - basic and diluted	43,500	27,149

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Dec. 31, 2018	$ 2,032	$ 27	$ 32,619	$ (36,993)	$ (162)	$ (2,477)
Balance, shares at Dec. 31, 2018	1,070,000	27,143,000
Issue common stock upon partial conversions of Senior Secured Convertible Note		$ 1	52			53
Issue common stock upon partial conversions of Senior Secured Convertible Note, shares		50,000
Series B Convertible Preferred Stock dividends declared	$ 64			(64)
Series B Convertible Preferred Stock dividends declared, shares	21,000
Stock-based compensation			350			350
Stock-based compensation - majority-owned subsidiary			4		105	109
Loss				(3,535)	(169)	(3,704)
Balance at Mar. 31, 2019	$ 2,096	$ 28	33,025	(40,592)	(226)	(5,669)
Balance, shares at Mar. 31, 2019	1,091,000	27,193,000
Balance at Dec. 31, 2018	$ 2,032	$ 27	32,619	(36,993)	(162)	(2,477)
Balance, shares at Dec. 31, 2018	1,070,000	27,143,000
Balance at Dec. 31, 2019	$ 2,296	$ 41	47,554	(53,715)	(814)	(4,638)
Balance, shares at Dec. 31, 2019	1,158,000	40,479,000
Issue common stock upon partial conversions of Senior Secured Convertible Note		$ 2	2,831			2,833
Issue common stock upon partial conversions of Senior Secured Convertible Note, shares		2,043,000
Series B Convertible Preferred Stock dividends declared	$ 69			(69)
Series B Convertible Preferred Stock dividends declared, shares	23,000
Stock-based compensation			328			328
Stock-based compensation - majority-owned subsidiary			3		13	16
Issue common stock - Employee Stock Purchase Plan			126			$ 126
Issue common stock - Employee Stock Purchase Plan, shares		154,000				154,000
Issue common stock - exercise Series S warrants		$ 1	11			$ 12
Issue common stock - exercise Series S warrants, shares		1,199,000
Issue common stock - conversion Series B Convertible Preferred Stock	$ (43)		43
Issue common stock - conversion Series B Convertible Preferred Stock, shares	(25,000)	25,000
Vesting of restricted stock awards
Vesting of restricted stock awards, shares		234,000
Issue common stock of majority-owned subsidiary exercise of stock options					5	5
Loss				(14,475)	(436)	(14,911)
Balance at Mar. 31, 2020	$ 2,322	$ 44	$ 50,896	$ (68,259)	$ (1,232)	$ (16,229)
Balance, shares at Mar. 31, 2020	1,156,000	44,134,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities
Net loss - before noncontrolling interest ("NCI")	$ (14,911)	$ (3,704)
Adjustments to reconcile net loss - before NCI to net cash used in operating activities
Depreciation expense	3	3
Stock-based compensation	344	459
Change in fair value - Senior Secured Convertible Notes	8,008	559
Debt extinguishments - Senior Secured Convertible Notes	1,188	1
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(364)	109
Accounts payable	1,804	(353)
Accrued expenses and other current liabilities	137	(944)
Net cash flows used in operating activities	(3,791)	(3,870)
Cash flows from investing activities
Purchase of equipment	(2)	(3)
Net cash flows used in investing activities	(2)	(3)
Cash flows from financing activities
Proceeds - exercise of stock options issued under equity incentive plan of majority-owned subsidiary	5
Proceeds - issue of Senior Convertible Note	6,300
Payment - Senior Secured Convertible Note - non-installment	(138)	(159)
Proceeds - issue common stock - Employee Stock Purchase Plan	126
Proceeds - exercise of Series S Warrants	12
Net cash flows provided by financing activities	6,305	(159)
Net increase (decrease) in cash	2,512	(4,032)
Cash, beginning of period	6,219	8,222
Cash, end of period	$ 8,731	$ 4,190

The Company and Description of

The Company and Description of the Business	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Description of the Business	Note 1 — The Company and Description of the Business PAVmed Inc. (“PAVmed” or the “Company”) together with its majority owned subsidiaries, Lucid Diagnostics, Inc (“Lucid Diagnostics” or “Lucid”) and Solys Diagnostics, Inc. (“Solys Diagnostics” or “Solys”) were organized to advance a broad pipeline of innovative medical technologies from concept to commercialization, employing a business model focused on capital efficiency and speed to market. The Company’s activities have focused on advancing the lead products towards regulatory approval and commercialization, protecting its intellectual property, and building its corporate infrastructure and management team. The Company operates in one segment as a medical device company. The ability of the Company to generate revenue depends upon the Company’s ability to successfully complete the development, obtain regulatory approval, and to initiate commercialization of its products and services. In this regard, to-date, the Company’s products and services have received clearances as follows: EsoCheck has received 510(k) marketing clearance from the FDA as an esophageal cell collection device in June 2019; EsoGuard completed the Clinical Laboratory Improvement Amendment (“CLIA”) and College of American Pathologists (“CAP”) certification as a Laboratory Developed Test (“LDT”) making it commercially available at Lucid’s contract diagnostic laboratory service provider in California in December 2019; and, CarpX, developed as a patented, single-use, disposable, minimally invasive device designed as a precision cutting tool to treat carpal tunnel syndrome while reducing recovery times, received 510(k) marketing clearance from the FDA in April 2020. The Company’s current operational activities are principally focused on the commercialization of EsoGuard and CarpX, and pursuing FDA approval and clearance of other lead products in our product portfolio pipeline, such as EsoGuard IVD and PortIO, while advancing DisappEAR and NextFlo through development. The Company has financed its operations principally through the public and private issuances of its common stock, preferred stock, warrants, and debt. All amounts in these accompanying notes to unaudited condensed consolidated financial statements are presented in thousands, if not otherwise noted as being presented in millions, except for per share amounts.

Financial Condition, Going Conc

Financial Condition, Going Concern and Management Plans	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Financial Condition, Going Concern and Management Plans	Note 2 — Financial Condition, Going Concern and Management Plans The Company is subject to all of the risks and uncertainties typically faced by diagnostic and medical device companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing R&D and clinical trials. The Company expects to continue incurring losses for the foreseeable future. The Company’s existing liquidity is not sufficient to fund its operations, anticipated capital expenditures and working capital funding until the Company reaches significant revenues. As such, the Company intends to rely of capital markets to obtain additional equity or debt financing, especially if the Company experiences downturns in its business that are more severe or longer than anticipated, or if the Company experiences significant increases in expense levels resulting from being a publicly-traded company or from expansion of operations. If the Company attempts to obtain additional equity or debt financing, the Company cannot assume that such financing will be available to the Company on favorable terms, or at all. As a result of recurring operating losses and net operating cash flow deficits there is substantial doubt about the Company’s ability to continue as a going concern within one year from the date of this filing. The unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 — Summary of Significant Accounting Policies Significant Accounting Policies Other than as described below, there have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 14, 2020. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority ownership interest and has controlling financial interest in Lucid Diagnostics Inc. and Solys Diagnostics Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity, including the recognition in the consolidated statement of the net loss attributable to the noncontrolling interest based on the respective minority ownership interest of each respective entity. The condensed consolidated balance sheet as of December 31, 2019, which has been derived from audited consolidated financial statements, and the unaudited condensed consolidated financial statements, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements at such date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s consolidated financial information. Certain items have been reclassified to conform to the current period presentation. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related consolidated financial information should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC on April 14, 2020. Use of Estimates In preparing unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements and estimating the fair value of financial instruments recorded as liabilities. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Recent Accounting Standards Adoption of new accounting Standard On January 1, 2020, we adopted ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), which aligns the accounting for share-based payments to nonemployees for goods and services with the requirements for accounting for share-based payments to employees under ASC 718 Compensation – Stock Compensation. ASU 2018-07 provides that nonemployee share-based payments are measured at the grant date at the fair value of the equity instruments to be provided to the nonemployee when the goods or services have been delivered. Prior to ASU 2018-07 nonemployee share-based payments were measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever could be more reliably measured. The adoption of ASU 2018-07 had no effect on the Company’s consolidated financial statements. On January 1, 2020, the Company adopted ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, In November 2018, the FASB issued ASU No. 2018-18, “Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606”

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	Note 4 — Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following as of: March 31, 2020 December 31, 2019 Deposits $ 39 $ 34 EsoCheck cell collection supplies 133 - Advanced payments to service providers and suppliers 520 294 Total prepaid expenses and other current assets $ 692 $ 328

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2020
Accrued Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 5 — Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following as of: March 31, 2020 December 31, 2019 Compensation related expenses $ 1,140 $ 1,075 EsoGuard License Agreement fee 223 223 Operating Expenses 160 89 Total accrued expenses and other current liabilities $ 1,523 $ 1,387

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 — Related Party Transactions During the three months ended March 31, 2020 and 2019 the Company incurred the following expenses with the minority shareholders of Lucid Diagnostics Inc.: For the three months ended March 31, 2020 2019 CWRU patent related fees $ 32 $ 31 Clinical supplies - EsoCheck 15 - EsoGuard Physician Inventors’ consulting agreements 38 38 Stock based compensation expense 6 24 Total $ 91 $ 93

Commitment and Contingencies

Commitment and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitment and Contingencies	Note 7 — Commitment and Contingencies Office Leases Total rent expense incurred under such office rental agreements was $50 and $33, for the three months ended March 31, 2020 and 2019, respectively. As of March 31, 2020, the Company’s future minimum lease payments for such office rental agreements are estimated to be a total of approximately $159 for the period April 1, 2020 to March 31, 2021.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 8 — Stock-Based Compensation PAVmed Inc. 2014 Long-Term Incentive Equity Plan - Stock Options Stock options issued and outstanding under the PAVmed Inc 2014 Long-Term Incentive Equity Plan (PAVmed Inc. 2014 Equity Plan”) for the period noted is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2019 5,204 $ 2.68 8.1 Granted 125 $ 2.05 Exercised — $ — 9.9 Forfeited — $ — Outstanding stock options at March 31, 2020 5,329 $ 2.66 8.0 Vested and exercisable stock options at March 31, 2020 3,604 $ 3.30 7.7 The aggregate intrinsic value of stock options granted under the PAVmed Inc. 2014 Equity as of March 31, 2020 was $2,058 with respect to such stock options outstanding and $850 with respect to such stock options vested and exercisable. The intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on March 31, 2020 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price. PAVmed Inc 2014 Long-Term Incentive Equity Plan - Restricted Stock Awards On March 15, 2019, a total of 700 restricted stock awards were granted to employees under the PAVmed Inc. 2014 Equity Plan, with such restricted stock awards vesting ratably on an annual basis over a three year period commencing March 15, 2020. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. On March 15, 2020, approximately 234 of such restricted stock awards vested. S PAVmed Inc Employee Stock Purchase Plan (“ESPP”) The PAVmed Inc. Employee Stock Purchase Plan (“ESPP”) provides eligible employees the opportunity to purchase shares of PAVmed Inc. common stock through payroll deductions during six month periods, wherein the purchase price per share of common stock is the lower of 85% of the quoted closing price per share of PAVmed Inc. common stock at the beginning or end of each six month share purchase period. The PAVmed Inc. ESPP share purchase dates are March 31 and September 30. On the March 31, 2020 ESPP purchase date, 154 shares of PAVmed Inc. common stock were issued for proceeds of approximately $0.1 million. Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan - Stock Options The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (“Lucid Diagnostics Inc. 2018 Equity Plan”) is separate and apart from the PAVmed Inc. 2014 Equity Plan discussed above. Stock options issued and outstanding under the Lucid Diagnostics Inc. 2018 Equity Plan for the period noted is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2019 995 $ 0.86 Granted — $ — Exercised 3 $ 1.50 Forfeited — $ — Outstanding stock options at March 31, 2020 992 $ 0.86 8.7 Vested and exercisable stock options at March 31, 2020 574 $ 0.83 8.6 Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan, have a ten year contractual term from date of grant, and vest ratably over twelve successive calendar quarters, with first vesting date in the quarter of the date of grant. During the three months ended March 31, 2020, 3 stock options issued under the Lucid Diagnostics Inc. 2018 Equity Plan were exercised for cash proceeds of $5, resulting in the issue of a corresponding number of shares of common stock of Lucid Diagnostics Inc. Stock-Based Compensation Expense Consolidated stock-based compensation expense recognized for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Three Months Ended March 31, 2020 2019 General and administrative expenses $ 277 $ 285 Research and development expenses 67 174 Total $ 344 $ 459 As of March 31, 2020, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc 2018 Equity Plan, as discussed above, is as follows: Unrecognized Remaining PAVmed Inc. 2014 Equity Plan Stock Options $ 1,107 1.0 year Restricted Stock Awards $ 474 1.9 years Lucid Diagnostics Inc. 2018 Equity Plan Stock Options $ 88 1.6 years Stock-based compensation expense recognized with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.81 per share and $0.93 per share during the three months ended March 31, 2020 and 2019, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Three Months Ended March 31, 2020 2019 Expected term of stock options (in years) 5.7 5.7 Expected stock price volatility 51 % 50 % Risk free interest rate 2.4 % 2.3 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan to non-employees under the previous provisions FASB ASC 505-50 in the prior year three months ended March 31, 2019, was based on a weighted average estimated fair value of such stock options of $1.99 per share, calculated using Black-Scholes valuation model weighted-average assumptions of 8.6 year contractual term, a 60% expected stock price volatility, a 2.4% risk free interest rate, and a 0% expected dividend rate. The restricted stock awards granted to employees under the PAVmed Inc. 2014 Equity Plan are measured at their grant date estimated fair value based on the date-of-grant quoted price per share of PAVmed Inc. common stock. The 700 restricted stock awards granted on March 15, 2019 had an aggregate fair value of approximately $742 with such stock-based compensation expense recognized ratably over the requisite service period, which is the three year vesting period as discussed above. The stock-based compensation expense recognized with respect to such restricted stock awards was approximately $62 and $21 in the three months ended March 31, 2020 and 2019, respectively, classified in general and administrative expenses, as presented above. Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.30 and $0.39 per share during the three months ended March 31, 2020 and 2019, respectively, and was calculated using the following weighted average Black-Scholes valuation model assumptions: Three Months Ended March 31, 2020 2019 Expected term of stock options (in years) 5.2 5.8 Expected stock price volatility 60 % 63 % Risk free interest rate 1.9 % 2.5 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan to non-employees under the previous provisions FASB ASC 505-50 in the prior year three months ended March 31, 2019, was based on a weighted average estimated fair value of such stock options of $0.57 per share, calculated using Black-Scholes valuation model weighted-average assumptions of 9.3 year contractual term, a 62% expected stock price volatility, a 2.5% risk free interest rate, and a 0% expected dividend rate. The Company uses the Black-Scholes valuation model to estimate the fair value of stock options granted under both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, which requires the Company to make certain estimates and assumptions, with the weighted-average valuation assumptions for stock-based awards, principally as follows: ● The expected term of stock options represents the period of time stock options are expected to be outstanding, which is the expected term derived using the simplified method and, through December 31, 2019 for non-employees (under the previous provisions FASB ASC 505-50), was the remaining contractual term; ● With respect to stock options granted under the PAVmed Inc. 2014 Equity Plan, the expected stock price volatility is based on the historical stock price volatility of PAVmed Inc. common stock (“PAVM”) and the volatilities of similar entities within the medical device industry over the period commensurate with the expected term, and through December 31, 2019 for non-employees (under the previous provisions FASB ASC 505-50), was the remaining contractual term of the respective stock option; and, with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan, the expected stock price volatility is based on the historical stock price volatilities of similar entities within the medical device industry over the period commensurate with the expected term, and through December 31, 2019 for non-employees (under the previous provisions FASB ASC 505-50), was the remaining contractual term of the respective stock option; ● The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period commensurate with the expected term of the stock option; and, ● The expected dividend yield is based on annual dividends of $0.00 as there has not been a dividend paid to-date, and there is no plan to pay dividends for the foreseeable future. The price per share of PAVmed Inc. common stock used in the computation of estimated fair value of stock options granted under the PAVmed Inc. 2014 Equity Plan is its quoted closing price per share. The price per share of Lucid Diagnostics Inc. common stock used in the computation of estimated fair value of stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan was estimated using a discounted cash flow method applied to a multi-year forecast of its future cash flows.

Financial Instruments Fair Valu

Financial Instruments Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Financial Instruments Fair Value Measurements	Note 9 — Financial Instruments Fair Value Measurements Recurring Fair Value Measurements The fair value hierarchy table for the periods indicated is as follows: Fair Value Measurement on a Recurring Basis at Reporting Date Using (1) Level-1 Level-2 Level-3 Inputs Inputs Inputs Total March 31, 2020 Senior Secured Convertible Note December 2018 $ 63 $ 63 Senior Secured Convertible Notes November 2019 $ — $ — $ 20,600 $ 20,600 Totals $ — $ — $ 20,663 $ 20,663 December 31, 2019 Senior Secured Convertible Note December 2018 $ 1,700 $ 1,700 Senior Secured Convertible Notes November 2019 $ — $ — $ 6,439 $ 6,439 Totals $ — $ — $ 8,139 $ 8,139 (1) As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs. There were no transfers between the respective Levels during the three-month period ended March 31, 2020. The November 2019 Senior Convertible Notes and the December 2018 Senior Secured Convertible Note are each accounted for under the ASC 825-10-15-4 fair value option (“FVO”) election. Under the FVO election the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. As provided for by ASC 825-10-50-30(b), the estimated fair value adjustment is presented as a single line item within other income (expense) in the accompanying unaudited condensed consolidated statement of operations. The following table presents changes in Level 3 liabilities measured at fair value for the three-month period ended March 31, 2020 and 2019. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs: Three months ended March 31, 2020: (ooo’s) except for per-share and percentages amounts December 2018 Senior Convertible Note November 2019 Senior Convertible Notes Fair Value Balance Sheet Components Other Income (Expense) Fair Value at December 31, 2019 $ 1,700 $ 6,439 $ 8,139 Cash proceeds - 6,300 6,300 Loss upon issue lender fees - 700 700 (700 ) Fair value adjustment at issue date - 2,561 2,561 (2,561 ) Repayments in cash - (138 ) (138 ) Payment of interest expense - - - Repayments in common stock (1,646 ) - (1,646 ) Change in fair value 9 4,738 4,747 (4,747 ) Fair Value at March 31, 2020 $ 63 $ 20,600 $ 20,663 $ (8,008 ) Fair Value Assumptions - March 31, 2020: Required rate of return 16% 12% Conversion Price $ 1.60 $ 1.60 Expected term (years) 0.04 1.52 Volatility 52% 68% Risk free rate 0% 0% Dividend yield 0% 0% Three months ended March 31, 2019: (ooo’s) except for per-share December Other Income (Expense) Fair Value at December 31, 2018 $ 7,903 Cash proceeds — Loss upon issue lender fees — Fair value adjustment at issue date — Repayments in cash (159 ) Payment of interest expense Repayments in common stock (52 ) Change in fair value 559 (559 ) Fair Value at March 31, 2019 $ 8,251 $ (559 ) Fair Value Assumptions - March 31, 2019: Required rate of return 11% Conversion Price $ 1.60 Expected term (years) 1.76 Volatility 50% Risk free rate 2% Dividend yield 0%

Outstanding Debt

Outstanding Debt	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Outstanding Debt	Note 10 — Outstanding Debt The following two tables summarize outstanding debt as of March 31, 2020 and December 31, 2019, respectively: (ooo’s) except for per-share amounts Maturity Stated Conversion Face Carrying December 2018 Senior Secured Convertible Note (1 ) 12/31/2020 7.875 % $ 1.60 $ 50 $ 63 November 2019 Senior Secured Convertible Note (2), (3) 9/30/2021 7.875 % $ 1.60 14,000 20,600 Balance as of March 31, 2020 $ 14,050 $ 20,663 December 2018 Senior Secured Convertible Note (1 ) 12/31/2020 7.875 % $ 1.60 $ 1,692 $ 1,700 November 2019 Senior Secured Convertible Note (2 ) 9/30/2021 7.875 % $ 1.60 7,000 $ 6,439 Balance as of December 31, 2019 $ 8,692 $ 8,139 (1) For the three months ended March 31, 2020 payments of approximately $1.6 million principal were made thru the issuance of approximately 2.0 million shares of common stock with a fair value of approximately $2.8 million resulting in a debt extinguishment loss of $1.2 million. (2) For the three months ended March 31, 2020 non-installment payments at the stated interest rate were made in the amount of approximately $138 thousand. (3) On March 30, 2020, the Series B investor notes were prepaid in the full amount of approximately $6.3 million. Upon payment of the investor note and in accordance with the securities purchase agreement, the Series B notes increased the stated interest rate from 3.0% to 7.875%. Also as a result of the prepayment, the Series B note terms became identical to the Series A notes and are accounted for under the fair value option election. For the three months ended March 31, 2020, non-installment payments at the applicable stated interest rate in the amount of approximately $52,500 were recognized as interest expense, and additionally, under a separate agreement, the Company recognized an expense in other income (expense) in the accompanying consolidated statement of operations, approximately $409,500 with respect to the placement agent advisory fee. The (cash) payment of 3.0% interest on the $7.0 million face value principal of the (unfunded) Series B 2019 Senior Convertible Notes, resulted in the recognition of $53 of interest expense during the three months ended March 31, 2020, included in other income (expense) in the accompanying unaudited condensed consolidated statement of operations. There was no such interest expense in the corresponding prior year period. Subsequent to March 31, 2020, with respect to the November 2019 Senior Convertible Notes, a total of $2,066 of Acceleration and Bi-Monthly Installment Amount face value principal repayments and corresponding non-installment payments of $68, were settled by the issue of 1,376 shares of common stock of the Company with a fair value of $3,374 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company).

Preferred Stock

Preferred Stock	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Preferred Stock	Note 11 — Preferred Stock In January 2020, the Company’s board-of-directors declared a Series B Convertible Preferred Stock dividend payment of earned but unpaid dividends as of December 31, 2019, payable as of January 1, 2020, of $69, with such dividend payment settled by the issue of an additional 23,182 shares of Series B Convertible Preferred Stock in accordance with the PAVmed Inc. Certificate of Designation of Preferences, Rights, and Limitations of Series B Convertible Preferred Stock (“Series B Convertible Preferred Stock Certificate of Designation”). In January 2019, the Company’s board-of-directors declared a Series B Convertible Preferred Stock dividend payment of earned but unpaid dividends as of December 31, 2018, payable as of January 1, 2019, of $64, with such dividend payment settled by the issue of an additional 21,413 shares of Series B Convertible Preferred Stock in accordance with the Series B Convertible Preferred Stock Certificate of Designation. Subsequent to March 31, 2020, in May 2020, the Company’s board-of-directors declared a Series B Convertible Preferred Stock dividend payment of earned but unpaid dividends as of March 31, 2020, payable as of April 1, 2019, of $70, with such dividend payment to be settled by the issue of an additional 23,481 shares of Series B Convertible Preferred Stock in accordance with the Series B Convertible Preferred Stock Certificate of Designation. The April 1, 2020 Series B Convertible Preferred Stock dividend payment was not recognized as a dividend payable liability as of March 31, 2020 as the Company’s board of directors had not declared such dividends payable as of such date.

Stockholders' Equity, Common St

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest	Note 12 — Stockholders’ Equity, Common Stock Purchase Warrants, and Noncontrolling Interest As of March 31, 2020, a total of 17,249,857 common stock purchase warrants were issued and outstanding, with a $1.68 per share weighted average exercise price; and, as of March 31, 2019, a total of 18,449,240 common stock purchase warrants were issued and outstanding with a $1.57 per share weighted average exercise price. During the three months ended March 31, 2020, 1,199,383 Series S Warrants were exercised for cash proceeds of $12, resulting in the issue of a corresponding number of shares of common stock of the Company. Noncontrolling Interest The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity for the periods indicated is as follows: Three Months Year Ended NCI - equity (deficit) - beginning of period $ (814 ) $ (162 ) Minority Interest investment in Solys Diagnostics Inc --- 889 Minority Interest share subscription receivable - Solys Diagnostics Inc. --- (889 ) Minority Interest Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise 5 --- Net loss attributable to NCI - Lucid Diagnostics Inc. (402 ) (801 ) Net loss attributable to NCI - Solys Diagnostics Inc. (34 ) (10 ) Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan 13 158 NCI - equity (deficit) - end of period $ (1,232 ) $ (814 )

Loss Per Share

Loss Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Loss Per Share	Note 13 —Loss Per Share Basic earnings (loss) per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per common share is computed similar to basic earnings (loss) per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Diluted weighted average common shares include common stock potentially issuable under the Company’s convertible notes, preferred stock, warrants and vested and unvested stock options. The following table sets forth the computation of earnings (loss) per share attributable to PAVmed Inc. and loss per share attributable to PAVmed Inc. common stockholders for the respective periods indicated: Three Months Ended March 31, 2020 2019 Numerator Net loss - before noncontrolling interest $ (14,911 ) $ (3,704 ) Net loss attributable to noncontrolling interest 436 169 Net loss - as reported, attributable to PAVmed Inc. $ (14,475 ) $ (3,535 ) Series B Convertible Preferred Stock dividends: $ (70 ) $ (65 ) Net loss attributable to PAVmed Inc. common stockholders $ (14,545 ) $ (3,600 ) Denominator Weighted average common shares outstanding basic and diluted 43,500 27,149 Loss per share Basic and diluted Net loss - as reported, attributable to PAVmed Inc. $ (0.33 ) $ (0.13 ) Net loss attributable to PAVmed Inc. common stockholders $ (0.33 ) $ (0.13 ) The following common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive: March 31, 2020 2019 PAVmed Inc. 2014 Equity Plan stock options and restricted stock awards 5,795 5,077 Unit purchase options - as to shares of common stock 53 53 Unit purchase options -as to shares underlying Series Z Warrants 53 53 Series Z Warrants 16,815 16,815 Series W Warrants 382 382 Series B Convertible Preferred Stock 1,156 1,091 Total 24,254 23,471

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 14 — Subsequent Events Other Matters The Company received approximately $0.3 million of proceeds from the Small Business Administration of the United States of America (“SBA”) in connection with the CARES Act Payroll Protection Program (“PPP”) related to loans available to certain companies during the pandemic resulting from “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2), commonly referred to by its resulting illness as “COVIID-19” (coronavirus disease-2019). The PPP loan proceeds have been recognized by the Company as a short-term debt obligation, requiring its repayment. Notwithstanding, the CARES Act provides for PPP loan recipients, including the Company, to apply to have the entire PPP loan repayment obligation forgiven. At this time, pending approval of the Company’s application for forgiveness, and while no assurance can be provided, the Company’s understanding of the loan forgiveness criteria indicates its PPP loan will be forgiven in its entirety. The Company entered into a Security Purchase Agreement for the issue of a Senior Secured Convertible Note in the principal amount of $4.1 million, resulting in the Company realizing cash proceeds of approximately $3.7 million, after the deduction of approximately $0.4 million of lender fees - referred to as the April 2020 Senior Convertible Note. Additionally, under a separate agreement, the Company incurred an expense of approximately $0.1 million with respect to the placement agent advisory fee. The April 2020 Senior Convertible Note has a 24 month maturity, a 7.875% interest rate per annum, and a voluntary conversion price of $5.00 per share of the Company’s common stock. On the maturity date, the Company will pay the holder in cash all remaining outstanding principal and unpaid interest thereon.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies Other than as described below, there have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 14, 2020.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority ownership interest and has controlling financial interest in Lucid Diagnostics Inc. and Solys Diagnostics Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity, including the recognition in the consolidated statement of the net loss attributable to the noncontrolling interest based on the respective minority ownership interest of each respective entity. The condensed consolidated balance sheet as of December 31, 2019, which has been derived from audited consolidated financial statements, and the unaudited condensed consolidated financial statements, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements at such date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s consolidated financial information. Certain items have been reclassified to conform to the current period presentation. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related consolidated financial information should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC on April 14, 2020.
Use of Estimates	Use of Estimates In preparing unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements and estimating the fair value of financial instruments recorded as liabilities. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows.
Recent Accounting Standards	Recent Accounting Standards Adoption of new accounting Standard On January 1, 2020, we adopted ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), which aligns the accounting for share-based payments to nonemployees for goods and services with the requirements for accounting for share-based payments to employees under ASC 718 Compensation – Stock Compensation. ASU 2018-07 provides that nonemployee share-based payments are measured at the grant date at the fair value of the equity instruments to be provided to the nonemployee when the goods or services have been delivered. Prior to ASU 2018-07 nonemployee share-based payments were measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever could be more reliably measured. The adoption of ASU 2018-07 had no effect on the Company’s consolidated financial statements. On January 1, 2020, the Company adopted ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, In November 2018, the FASB issued ASU No. 2018-18, “Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606”

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following as of: March 31, 2020 December 31, 2019 Deposits $ 39 $ 34 EsoCheck cell collection supplies 133 - Advanced payments to service providers and suppliers 520 294 Total prepaid expenses and other current assets $ 692 $ 328

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Accrued Liabilities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following as of: March 31, 2020 December 31, 2019 Compensation related expenses $ 1,140 $ 1,075 EsoGuard License Agreement fee 223 223 Operating Expenses 160 89 Total accrued expenses and other current liabilities $ 1,523 $ 1,387

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Schedule of Incurred Expenses of Minority Shareholders	During the three months ended March 31, 2020 and 2019 the Company incurred the following expenses with the minority shareholders of Lucid Diagnostics Inc.: For the three months ended March 31, 2020 2019 CWRU patent related fees $ 32 $ 31 Clinical supplies - EsoCheck 15 - EsoGuard Physician Inventors’ consulting agreements 38 38 Stock based compensation expense 6 24 Total $ 91 $ 93

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Summarizes Information About Stock Options	Stock options issued and outstanding under the PAVmed Inc 2014 Long-Term Incentive Equity Plan (PAVmed Inc. 2014 Equity Plan”) for the period noted is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2019 5,204 $ 2.68 8.1 Granted 125 $ 2.05 Exercised — $ — 9.9 Forfeited — $ — Outstanding stock options at March 31, 2020 5,329 $ 2.66 8.0 Vested and exercisable stock options at March 31, 2020 3,604 $ 3.30 7.7 Stock options issued and outstanding under the Lucid Diagnostics Inc. 2018 Equity Plan for the period noted is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2019 995 $ 0.86 Granted — $ — Exercised 3 $ 1.50 Forfeited — $ — Outstanding stock options at March 31, 2020 992 $ 0.86 8.7 Vested and exercisable stock options at March 31, 2020 574 $ 0.83 8.6
Schedule of Stock-Based Compensation Awards Granted	Consolidated stock-based compensation expense recognized for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Three Months Ended March 31, 2020 2019 General and administrative expenses $ 277 $ 285 Research and development expenses 67 174 Total $ 344 $ 459
Schedule of Unrecognised Compensation Expense	As of March 31, 2020, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc 2018 Equity Plan, as discussed above, is as follows: Unrecognized Remaining PAVmed Inc. 2014 Equity Plan Stock Options $ 1,107 1.0 year Restricted Stock Awards $ 474 1.9 years Lucid Diagnostics Inc. 2018 Equity Plan Stock Options $ 88 1.6 years
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	Stock-based compensation expense recognized with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.81 per share and $0.93 per share during the three months ended March 31, 2020 and 2019, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Three Months Ended March 31, 2020 2019 Expected term of stock options (in years) 5.7 5.7 Expected stock price volatility 51 % 50 % Risk free interest rate 2.4 % 2.3 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.30 and $0.39 per share during the three months ended March 31, 2020 and 2019, respectively, and was calculated using the following weighted average Black-Scholes valuation model assumptions: Three Months Ended March 31, 2020 2019 Expected term of stock options (in years) 5.2 5.8 Expected stock price volatility 60 % 63 % Risk free interest rate 1.9 % 2.5 % Expected dividend yield 0 % 0 %

Financial Instruments Fair Va_2

Financial Instruments Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis	The fair value hierarchy table for the periods indicated is as follows: Fair Value Measurement on a Recurring Basis at Reporting Date Using (1) Level-1 Level-2 Level-3 Inputs Inputs Inputs Total March 31, 2020 Senior Secured Convertible Note December 2018 $ 63 $ 63 Senior Secured Convertible Notes November 2019 $ — $ — $ 20,600 $ 20,600 Totals $ — $ — $ 20,663 $ 20,663 December 31, 2019 Senior Secured Convertible Note December 2018 $ 1,700 $ 1,700 Senior Secured Convertible Notes November 2019 $ — $ — $ 6,439 $ 6,439 Totals $ — $ — $ 8,139 $ 8,139 (1) As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs. There were no transfers between the respective Levels during the three-month period ended March 31, 2020.
Schedule of Senior Convertible Note Estimated Fair Value	Three months ended March 31, 2020: (ooo’s) except for per-share and percentages amounts December 2018 Senior Convertible Note November 2019 Senior Convertible Notes Fair Value Balance Sheet Components Other Income (Expense) Fair Value at December 31, 2019 $ 1,700 $ 6,439 $ 8,139 Cash proceeds - 6,300 6,300 Loss upon issue lender fees - 700 700 (700 ) Fair value adjustment at issue date - 2,561 2,561 (2,561 ) Repayments in cash - (138 ) (138 ) Payment of interest expense - - - Repayments in common stock (1,646 ) - (1,646 ) Change in fair value 9 4,738 4,747 (4,747 ) Fair Value at March 31, 2020 $ 63 $ 20,600 $ 20,663 $ (8,008 ) Three months ended March 31, 2019: (ooo’s) except for per-share December Other Income (Expense) Fair Value at December 31, 2018 $ 7,903 Cash proceeds — Loss upon issue lender fees — Fair value adjustment at issue date — Repayments in cash (159 ) Payment of interest expense Repayments in common stock (52 ) Change in fair value 559 (559 ) Fair Value at March 31, 2019 $ 8,251 $ (559 )
Schedule of Fair Value Assumption Used	Fair Value Assumptions - March 31, 2020: Required rate of return 16% 12% Conversion Price $ 1.60 $ 1.60 Expected term (years) 0.04 1.52 Volatility 52% 68% Risk free rate 0% 0% Dividend yield 0% 0% Fair Value Assumptions - March 31, 2019: Required rate of return 11% Conversion Price $ 1.60 Expected term (years) 1.76 Volatility 50% Risk free rate 2% Dividend yield 0%

Outstanding Debt (Tables)

Outstanding Debt (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Summary of Outstanding Debt	The following two tables summarize outstanding debt as of March 31, 2020 and December 31, 2019, respectively: (ooo’s) except for per-share amounts Maturity Stated Conversion Face Carrying December 2018 Senior Secured Convertible Note (1 ) 12/31/2020 7.875 % $ 1.60 $ 50 $ 63 November 2019 Senior Secured Convertible Note (2), (3) 9/30/2021 7.875 % $ 1.60 14,000 20,600 Balance as of March 31, 2020 $ 14,050 $ 20,663 December 2018 Senior Secured Convertible Note (1 ) 12/31/2020 7.875 % $ 1.60 $ 1,692 $ 1,700 November 2019 Senior Secured Convertible Note (2 ) 9/30/2021 7.875 % $ 1.60 7,000 $ 6,439 Balance as of December 31, 2019 $ 8,692 $ 8,139 (1) For the three months ended March 31, 2020 payments of approximately $1.6 million principal were made thru the issuance of approximately 2.0 million shares of common stock with a fair value of approximately $2.8 million resulting in a debt extinguishment loss of $1.2 million. (2) For the three months ended March 31, 2020 non-installment payments at the stated interest rate were made in the amount of approximately $138 thousand. (3) On March 30, 2020, the Series B investor notes were prepaid in the full amount of approximately $6.3 million. Upon payment of the investor note and in accordance with the securities purchase agreement, the Series B notes increased the stated interest rate from 3.0% to 7.875%. Also as a result of the prepayment, the Series B note terms became identical to the Series A notes and are accounted for under the fair value option election. For the three months ended March 31, 2020, non-installment payments at the applicable stated interest rate in the amount of approximately $52,500 were recognized as interest expense, and additionally, under a separate agreement, the Company recognized an expense in other income (expense) in the accompanying consolidated statement of operations, approximately $409,500 with respect to the placement agent advisory fee.

Stockholders' Equity, Common _2

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of Noncontrolling Interest	The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity for the periods indicated is as follows: Three Months Year Ended NCI - equity (deficit) - beginning of period $ (814 ) $ (162 ) Minority Interest investment in Solys Diagnostics Inc --- 889 Minority Interest share subscription receivable - Solys Diagnostics Inc. --- (889 ) Minority Interest Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise 5 --- Net loss attributable to NCI - Lucid Diagnostics Inc. (402 ) (801 ) Net loss attributable to NCI - Solys Diagnostics Inc. (34 ) (10 ) Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan 13 158 NCI - equity (deficit) - end of period $ (1,232 ) $ (814 )

Loss Per Share (Tables)

Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share	The following table sets forth the computation of earnings (loss) per share attributable to PAVmed Inc. and loss per share attributable to PAVmed Inc. common stockholders for the respective periods indicated: Three Months Ended March 31, 2020 2019 Numerator Net loss - before noncontrolling interest $ (14,911 ) $ (3,704 ) Net loss attributable to noncontrolling interest 436 169 Net loss - as reported, attributable to PAVmed Inc. $ (14,475 ) $ (3,535 ) Series B Convertible Preferred Stock dividends: $ (70 ) $ (65 ) Net loss attributable to PAVmed Inc. common stockholders $ (14,545 ) $ (3,600 ) Denominator Weighted average common shares outstanding basic and diluted 43,500 27,149 Loss per share Basic and diluted Net loss - as reported, attributable to PAVmed Inc. $ (0.33 ) $ (0.13 ) Net loss attributable to PAVmed Inc. common stockholders $ (0.33 ) $ (0.13 )
Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share	The following common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive: March 31, 2020 2019 PAVmed Inc. 2014 Equity Plan stock options and restricted stock awards 5,795 5,077 Unit purchase options - as to shares of common stock 53 53 Unit purchase options -as to shares underlying Series Z Warrants 53 53 Series Z Warrants 16,815 16,815 Series W Warrants 382 382 Series B Convertible Preferred Stock 1,156 1,091 Total 24,254 23,471

The Company and Description o_2

The Company and Description of the Business (Details Narrative)	3 Months Ended
	Mar. 31, 2020Integer
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	1

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Prepaid Expense and Other Assets, Current [Abstract]
Deposits	$ 39	$ 34
EsoCheck cell collection supplies	133
Advanced payments to service providers and suppliers	520	294
Total prepaid expenses and other current assets	$ 692	$ 328

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accrued Liabilities [Abstract]
Compensation related expenses	$ 1,140	$ 1,075
EsoGuard License Agreement fee	223	223
Operating Expenses	160	89
Total accrued expenses and other current liabilities	$ 1,523	$ 1,386

Related Party Transactions - Sc

Related Party Transactions - Schedule of Incurred Expenses of Minority Shareholders (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Related Party Transactions [Abstract]
CWRU patent related fees	$ 32	$ 31
Clinical supplies - EsoCheck	15
EsoGuard Physician Inventors' consulting agreements	38	38
Stock based compensation expense	6	24
Total	$ 91	$ 93

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Rent expense	$ 50	$ 33
April 1, 2020 to March 31, 2021 [Member]
Future minimum lease payments	$ 159

Stock-Based Compensation - (Det

Stock-Based Compensation - (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Mar. 15, 2019	Apr. 30, 2020	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation expense			$ 344	$ 459
General and Administrative Expenses [Member]
Stock-based compensation expense			$ 277	$ 285
Restricted Stock [Member] | Subsequent Event [Member]
Number of restricted stock award granted		1,000,000
Number of stock purchase of common stock		1,100,000
Stock option exercise per share		$ 2.19
Employee Stock Purchase Plan [Member]
Vesting portion of stock			ESPP share purchase dates are March 31 and September 30. On the March 31, 2020 ESPP purchase date, 154 shares of PAVmed Inc. common stock were issued for proceeds of approximately $0.1 million.
Purchase price per share percentage on ESPP plan			85.00%
Proceeds from issuance of common stock			$ 100
2014 Equity Plan [Member]
Aggregate Intrinsic Value			2,058
Aggregate Intrinsic Value, Vested and exercisable stock options			$ 850
Weighted average fair value of stock options				$ 0.93
Expected dividend rate			0.00%
2014 Equity Plan [Member] | Non-employees [Member]
Weighted average fair value of stock options				$ 1.99
Contractual term				8 years 7 months 6 days
Expected stock price volatility				60.00%
Risk free interest rate				2.40%
Expected dividend rate				0.00%
2014 Equity Plan [Member] | Restricted Stock [Member]
Number of restricted stock award granted	700
Stock-based compensation expense	$ 742
2014 Equity Plan [Member] | Restricted Stock [Member] | General and Administrative Expenses [Member]
Stock-based compensation expense			$ 62	$ 21
2014 Equity Plan [Member] | Restricted Stock [Member] | Employees [Member]
Number of restricted stock award granted	700
Vesting portion of stock	2014 Equity Plan, with such restricted stock awards vesting ratably on an annual basis over a three year period commencing March 15, 2020.
Restricted stock awards vested	234
2018 Long-Term Incentive Equity Plan [Member]
Number of common stock issued			3
Weighted average fair value of stock options			$ 0.30	$ 0.39
Contractual term of stock options			10 years
2018 Long-Term Incentive Equity Plan [Member] | Non-employees [Member]
Weighted average fair value of stock options				$ 0.57
Contractual term				9 years 3 months 19 days
Expected stock price volatility				62.00%
Risk free interest rate				2.50%
Expected dividend rate				0.00%
2018 Stock Plan [Member]
Proceeds from issuance of common stock			$ 5

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Summarizes Information About Stock Options (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2020$ / sharesshares
2014 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	5,204
Number of Stock Options, Granted | shares	125
Number of Stock Option, Exercised | shares
Number of Stock Option, Forfeited | shares
Number of Stock Options Outstanding, Ending Balance | shares	5,329
Number of Stock Options Vested and exercisable stock options | shares	3,604
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 2.68
Weighted Average Exercise Price, Granted | $ / shares	2.05
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Ending Balance | $ / shares	2.66
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 3.30
Remaining Contractual Term (Years) stock options, Beginning	8 years 1 month 6 days
Remaining Contractual Term (Years) stock options, Exercised	9 years 10 months 25 days
Remaining Contractual Term (Years) stock options, Ending Balance	8 years
Remaining Contractual Term (Years), Vested and exercisable stock options	7 years 8 months 12 days
2018 Stock Plan [Member] | Lucid Diagnostics Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	995
Number of Stock Options, Granted | shares
Number of Stock Option, Exercised | shares	3
Number of Stock Option, Forfeited | shares
Number of Stock Options Outstanding, Ending Balance | shares	992
Number of Stock Options Vested and exercisable stock options | shares	574
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.86
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares	1.50
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Ending Balance | $ / shares	0.86
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 0.83
Remaining Contractual Term (Years) stock options, Ending Balance	8 years 8 months 12 days
Remaining Contractual Term (Years), Vested and exercisable stock options	8 years 7 months 6 days

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Stock-Based Compensation Awards Granted (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 344	$ 459
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	277	285
Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 67	$ 174

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Unrecognised Compensation Expense (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
2014 Long Term Incentive Equity Plan [Member] | Parent Company [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 1,107
Remaining Service Period	1 year
2014 Long Term Incentive Equity Plan [Member] | Parent Company [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 474
Remaining Service Period	1 year 10 months 25 days
2018 Long Term Incentive Equity Plan [Member] | Stock Options [Member] | Lucid Diagnostics Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 88
Remaining Service Period	1 year 7 months 6 days

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
2014 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 8 months 12 days	5 years 8 months 12 days
Expected stock price volatility	51.00%	50.00%
Risk free interest rate	2.40%	2.30%
Expected dividend yield	0.00%	0.00%
2018 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 2 months 12 days	5 years 9 months 18 days
Expected stock price volatility	60.00%	63.00%
Risk free interest rate	1.90%	2.50%
Expected dividend yield	0.00%	0.00%

Financial Instruments Fair Va_3

Financial Instruments Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands		Mar. 31, 2020	Dec. 31, 2019
Fair value of liability	[1]	$ 20,663	$ 8,139
December 2018 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]	63
December 2018 Senior Convertible Note [Member]
Fair value of liability	[1]		1,700
November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]	20,600	6,439
Fair Value, Inputs, Level 1 [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | December 2018 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | December 2018 Senior Convertible Note [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | December 2018 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | December 2018 Senior Convertible Note [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 3 [Member]
Fair value of liability	[1]	20,663	8,139
Fair Value, Inputs, Level 3 [Member] | December 2018 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]	63
Fair Value, Inputs, Level 3 [Member] | December 2018 Senior Convertible Note [Member]
Fair value of liability	[1]		1,700
Fair Value, Inputs, Level 3 [Member] | November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]	$ 20,600	$ 6,439
[1]	As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs. There were no transfers between the respective Levels during the three-month period ended March 31, 2020.

Financial Instruments Fair Va_4

Financial Instruments Fair Value Measurements - Schedule of Senior Convertible Note Estimated Fair Value (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Fair Value - Beginning	$ 8,139
Cash proceeds	6,300
Loss upon issue lender fees	700
Fair value adjustment at issue date	2,561
Repayments in cash	(138)
Payment of interest expense
Repayments in common stock	(1,646)
Change in fair value	4,747
Fair Value - Ending	20,663
December 2018 Senior Secured Convertible Note [Member]
Fair Value - Beginning	1,700	$ 7,903
Cash proceeds
Loss upon issue lender fees
Fair value adjustment at issue date
Repayments in cash		(159)
Payment of interest expense
Repayments in common stock	(1,646)	(52)
Change in fair value	9	559
Fair Value - Ending	63	8,251
November 2019 Senior Secured Convertible Notes [Member]
Fair Value - Beginning	6,439
Cash proceeds	6,300
Loss upon issue lender fees	700
Fair value adjustment at issue date	2,561
Repayments in cash	(138)
Payment of interest expense
Repayments in common stock
Change in fair value	4,738
Fair Value - Ending	20,600
Other Income (Expense) [Member]
Loss upon issue lender fees	(700)
Fair value adjustment at issue date	(2,561)
Change in fair value	(4,747)	(559)
Fair Value - Ending	$ (8,008)	$ (559)

Financial Instruments Fair Va_5

Financial Instruments Fair Value Measurements - Schedule of Fair Value Assumption Used (Details) - $ / shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
December 2018 Senior Convertible Note [Member]
Required rate of return	16.00%	11.00%
Conversion Price	$ 1.60	$ 1.60
Expected term (years)	15 days	1 year 9 months 3 days
Volatility	52.00%	50.00%
Risk free rate	0.00%	2.00%
Dividend yield	0.00%	0.00%
November 2019 Senior Secured Convertible Notes [Member]
Required rate of return	12.00%
Conversion Price	$ 1.60
Expected term (years)	1 year 6 months 7 days
Volatility	68.00%
Risk free rate	0.00%
Dividend yield	0.00%

Outstanding Debt (Details Narra

Outstanding Debt (Details Narrative)	2 Months Ended	3 Months Ended
	May 18, 2020USD ($)shares	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Accelerated Installment Amount principal repayments - common stock	$ 2,066,000
Bi-monthly Installment Amount principal repayments - common stock	2,066,000
Non-installment payments - common stock	$ 68,000
Fair Value - Common Stock Issued, shares | shares	1,376
Fair Value - Common Stock Issued	$ 3,374,000
Principal amount		$ 14,050	$ 8,692
Series B 2019 Convertible Notes [Member]
Cash payment, interest rate percentage		0.030
Principal amount		$ 7,000,000
Interest expenses		$ 53,000

Outstanding Debt - Summary of O

Outstanding Debt - Summary of Outstanding Debt (Details) - USD ($)		3 Months Ended		12 Months Ended
		Mar. 31, 2020		Dec. 31, 2019
Face Value		$ 14,050		$ 8,692
Carrying Value		$ 20,663		$ 8,139
December 2018 Senior Convertible Note [Member]
Maturity Date	[1]	Dec. 31, 2020		Dec. 31, 2020
Stated Interest Rate	[1]	7.875%		7.875%
Conversion Price	[1]	$ 1.60		$ 1.60
Face Value	[1]	$ 50		$ 1,692
Carrying Value	[1]	$ 63		$ 1,700
November 2019 Senior Convertible Notes [Member]
Maturity Date	[2]	Sep. 30, 2021	[3]	Sep. 30, 2021
Stated Interest Rate	[2]	7.875%	[3]	7.875%
Conversion Price	[2]	$ 1.60	[3]	$ 1.60
Face Value	[2]	$ 14,000	[3]	$ 7,000
Carrying Value	[3]	$ 20,600	[2]	$ 6,439
[1]	For the three months ended March 31, 2020 payments of approximately $1.6 million principal were made thru the issuance of approximately 2.0 million shares of common stock with a fair value of approximately $2.8 million resulting in a debt extinguishment loss of $1.2 million.
[2]	For the three months ended March 31, 2020 non-installment payments at the stated interest rate were made in the amount of approximately $138 thousand.
[3]	On March 30, 2020, the Series B investor notes were prepaid in the full amount of approximately $6.3 million. Upon payment of the investor note and in accordance with the securities purchase agreement, the Series B notes increased the stated interest rate from 3.0% to 7.875%. Also as a result of the prepayment, the Series B note terms became identical to the Series A notes and are accounted for under the fair value option election. For the three months ended March 31, 2020, non-installment payments at the applicable stated interest rate in the amount of approximately $52,500 were recognized as interest expense, and additionally, under a separate agreement, the Company recognized an expense in other income (expense) in the accompanying consolidated statement of operations, approximately $409,500 with respect to the placement agent advisory fee.

Outstanding Debt - Summary of_2

Outstanding Debt - Summary of Outstanding Debt (Details) (Parenthetical) - USD ($)	1 Months Ended	3 Months Ended
	Mar. 30, 2020	Mar. 31, 2020
Principal amount		$ 1,600,000
Issuance of common stock, shares		2,000,000
Issuance of common stock, value		$ 2,800,000
Debt extinguishment loss		1,200,000
Non installment amount		138,000
Interest expense		$ 52,500
Series B Investor Note [Member]
Prepaid in full amount	$ 6,300,000
Series B Investor Note [Member] | Placement Agent [Member]
Advisory fee	$ 409,500
Series B Investor Note [Member] | Minimum [Member]
Stated Interest Rate	3.00%
Series B Investor Note [Member] | Maximum [Member]
Stated Interest Rate	787.50%

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - Series B Convertible Preferred Stock [Member] - USD ($) $ in Thousands	2 Months Ended	3 Months Ended
	May 22, 2020	Mar. 31, 2020	Mar. 31, 2019	Apr. 01, 2020	Jan. 02, 2020	Jan. 02, 2019
Dividend payable					$ 69	$ 64
Additional shares of dividend		$ 23,182	$ 21,413
Subsequent Event [Member]
Dividend payable				$ 70
Additional shares of dividend	$ 23,481

Stockholders' Equity, Common _3

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Common stock purchase warrants	17,249,857	18,449,240
Warrants exercise price	$ 1.68	$ 1.57
Proceeds from warrants exercised	$ 12
Series S Warrants [Member]
Warrants exercised	1,199,383
Proceeds from warrants exercised	$ 12

Stockholders' Equity, Common _4

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest - Schedule of Noncontrolling Interest (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
NCI - equity (deficit) - beginning of period	$ (814)
Net loss attributable to NCI	(436)	$ (169)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan	328	350
NCI - equity (deficit) - end of period	(1,232)		$ (814)
Non-controlling Interest [Member]
NCI - equity (deficit) - beginning of period	(814)	(162)	(162)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan
NCI - equity (deficit) - end of period	(1,232)		(814)
Non-controlling Interest [Member] | Solys Diagnostics Inc. [Member]
Minority Interest investment in Solys Diagnostics Inc			889
Minority Interest share subscription receivable - Solys Diagnostics Inc.			(889)
Net loss attributable to NCI	(34)		(10)
Non-controlling Interest [Member] | Lucid Diagnostics Inc [Member]
Minority Interest Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise	5
Net loss attributable to NCI	(402)		(801)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan	$ 13		$ 158

Loss Per Share - Schedule of Co

Loss Per Share - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Net loss - before noncontrolling interest	$ (14,911)	$ (3,704)
Net loss attributable to noncontrolling interest	436	169
Net loss - as reported, attributable to PAVmed Inc.	(14,475)	(3,535)
Series B Convertible Preferred Stock dividends	(70)	(65)
Net loss attributable to PAVmed Inc. common stockholders	$ (14,545)	$ (3,600)
Weighted average common shares outstanding basic and diluted	43,500	27,149
Basic and diluted - Net loss - as reported, attributable to PAVmed Inc.	$ (0.33)	$ (0.13)
Basic and diluted - Net loss attributable to PAVmed Inc. common stockholders	$ (0.33)	$ (0.13)

Loss Per Share - Schedule of An

Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive securities excluded from computation of diluted weighted shares outstanding	24,254	23,471
PAVmed Inc. 2014 Equity Plan Stock Options and Restricted Awards [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	5,795	5,077
Unit Purchase Options as to Shares of common stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	53	53
Unit Purchase Options as to Shares Underlying Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	53	53
Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	16,815	16,815
Series W Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	382	382
Series B Convertible Preferred Stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	1,156	1,091

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended
	May 18, 2020	Mar. 31, 2020
Principal amount		$ 1,600,000
Securities Purchase Agreement [Member] | Subsequent Event [Member] | Convertible Promissory Notes [Member]
Proceeds from issuance of debt	$ 300,000
Principal amount	4,100,000
Financial advisory fees	3,700,000
Lender fees	400,000
Incurred expense	$ 100,000
Debt instrument maturity period	24 months
Debt instrument interest rate percentage	7.875%
Voluntary conversion rate	$ 5